IDiyas

For the Inventor, By the Inventor

Boston, MA, United States of America

Natasja Brooijmans

USPTO Granted Patents = 13 

 

Average Co-Inventor Count = 6.2

ph-index = 6

Forward Citations = 222(Granted Patents)


Location History:

  • Cambridge, MA (US) (2023)
  • Boston, MA (US) (2014 - 2024)

Company Filing History:

goldMedal13 out of 60 
 
Blueprint Medicines Corporation
 patents

Years Active: 2014-2024

Loading Chart...
Loading Chart...
13 patents (USPTO):
1. 12172983 - EGFR inhibitors (2024-12-24),
2. 11970498 - CDK2 inhibitors (2024-04-30),
3. 11932648 - CDK2 inhibitors (2024-03-19),
4. 11718602 - EGFR inhibitors (2023-08-08),
5. 11634422 - Inhibitors of activin receptor-like kinase (2023-04-25),
6. 11046697 - Compounds and compositions useful for treating disorders related to NTRK (2021-06-29),
7. 10774070 - 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors (2020-09-15),
8. 10233186 - Inhibitors of activin receptor-like kinase (2019-03-19),
9. 10202365 - 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors (2019-02-12),
10. 10017512 - Compounds and compositions useful for treating disorders related to NTRK (2018-07-10),
11. 9340514 - Inhibitors of the fibroblast growth factor receptor (2016-05-17),
12. 9126951 - Inhibitors of the fibroblast growth factor receptor (2015-09-08),
13. 8802697 - Inhibitors of the fibroblast growth factor receptor (2014-08-12),

Title: Natasja Brooijmans: Pioneering Cancer Researcher and Inventor

Introduction: Natasja Brooijmans is a prominent inventor based in Boston, MA, who has made significant contributions to the field of cancer research. With a remarkable portfolio of 13 patents, she is dedicated to developing innovative therapeutic solutions to combat cancer through her work.

Latest Patents: Among her recent innovations, Natasja has developed EGFR inhibitors, which provide a compound useful for treating various cancers. This invention is represented by a specific structural formula or its pharmaceutically acceptable salts. Additionally, she has contributed to the development of CDK2 inhibitors, another vital therapeutic compound aimed at treating cancer.

Career Highlights: Natasja Brooijmans is currently affiliated with Blueprint Medicines Corporation, where she leverages her expertise in medicinal chemistry and cancer biology to advance groundbreaking cancer therapies. Throughout her career, she has focused on translating innovative ideas into actionable medical treatments.

Collaborations: Natasja has had the opportunity to collaborate with distinguished colleagues such as Joseph L. Kim and Neil Bifulco. These partnerships have enabled her to enhance her research and broaden the impact of their collective efforts in the fight against cancer.

Conclusion: As an accomplished inventor in the pharmaceutical sector, Natasja Brooijmans continues to make strides in cancer research. Her dedication to innovation and collaboration cements her legacy as a leading figure in the development of life-changing therapeutic solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…